Literature DB >> 17214328

Successful treatment of a patient with gastric and duodenal metastases from large cell carcinoma of the lung with carboplatin and gemcitabine.

Kadoaki Ohashi1, Katsuyuki Kiura, Nagio Takigawa, Takaaki Mizushima, Hideo Ino, Masahiro Tabata, Hiroshi Ueoka, Mitsune Tanimoto.   

Abstract

A 62-year-old man with large cell carcinoma of the lung underwent a right upper lobectomy and four months later demonstrated a relapse in the stomach and duodenum. He received systemic chemotherapy consisting of carboplatin and gemcitabine. After the first cycle of chemotherapy, the duodenal lesion disappeared, however, the gastric lesion demonstrated no response. Considering the risk of bleeding or perforation, a partial gastroduodenal resection was therefore performed. Subsequently, he received adjuvant chemotherapy with the same regimen. He has since been doing well for 24 months after the recurrence. Although the prognosis for patients with gastrointestinal metastases from lung cancer tends to be extremely poor, treatment with chemotherapy and a metastasectomy have resulted in this patient, achieving a long survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17214328

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  An Unusually Aggressive Large Cell Carcinoma of the Lung: Undiagnosed until Autopsy.

Authors:  Kartikeya Rajdev; Abdul Hasan Siddiqui; Uroosa Ibrahim; Prateek Patibandla; Tahir Khan; Dany El-Sayegh
Journal:  Cureus       Date:  2018-02-19

2.  Gastrointestinal metastasis of primary lung cancer: An analysis of 366 cases.

Authors:  Yue Hu; Noah Feit; Yanqin Huang; Wenhong Xu; Shu Zheng; Xiuzhen Li
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

3.  Gastric Metastasis of Primary Lung Cancer: Case Report and Systematic Review With Pooled Analysis.

Authors:  Dong Tang; Jianjian Lv; Zhijing Liu; Shuhui Zhan; Yuqiang Gao
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.